Boehringer Ingelheim expanded its oncology collaboration with Sino Biopharmaceutical (SBP Group) under a strategic multi-program option and license agreement covering six preclinical biologics programs built on SBP’s antibody-drug conjugate (ADC) and T-cell engager (TcE) platforms. The deal structure includes $358 million in upfront and near-term payments and up to $7 billion in milestone payments plus royalties, with SBP overseeing early development before Boehringer options for exclusive development, manufacturing, and commercialization. The arrangement deepens a partnership framework Boehringer launched in 2024 and is designed to broaden its differentiated cancer portfolio across both cell-directed and immuno-oncology approaches. Five programs originate from LaNova Medicines, and one from Beijing Tide Pharmaceutical, highlighting SBP’s internal pipeline breadth. From an industry standpoint, the agreement underscores how large-cap oncology players are using platform-based licensing to accelerate preclinical diversification, particularly in ADC and T-cell engager modalities where speed to proof-of-concept and translation risk remain key gating factors.